Cargando…

A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain

BACKGROUND: Many Osteoarthritis (OA) patients report with clinical features to their pain that cannot be explained by purely peripheral mechanisms. Yet, the analgesic agents available that tackle centrally driven chronic pain often provide only partial pain relief, or have dose‐limiting side effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Lockwood, Stevie Margaret, Dickenson, Anthony H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618140/
https://www.ncbi.nlm.nih.gov/pubmed/30821870
http://dx.doi.org/10.1002/ejp.1386
_version_ 1783433851974975488
author Lockwood, Stevie Margaret
Dickenson, Anthony H.
author_facet Lockwood, Stevie Margaret
Dickenson, Anthony H.
author_sort Lockwood, Stevie Margaret
collection PubMed
description BACKGROUND: Many Osteoarthritis (OA) patients report with clinical features to their pain that cannot be explained by purely peripheral mechanisms. Yet, the analgesic agents available that tackle centrally driven chronic pain often provide only partial pain relief, or have dose‐limiting side effects. We explored a combination therapy of the centrally acting analgesic agents tapentadol and pregabalin, to investigate if they could be used in combination to provide superior analgesia. METHODS: Using electrophysiological single‐unit recordings taken from spinal wide dynamic range neurons, Diffuse Noxious Inhibitory Controls (DNIC) were assessed as a marker of potential changes in descending controls in a monoiodoacetate (MIA) model of OA. We investigated if a subcutaneous injection of tapentadol or pregabalin, both alone and in combination, inhibited neuronal responses and restored the expression of DNIC, quantified as a reduction in neuronal firing in the presence of a conditioning noxious stimulus. RESULTS: Tapentadol restored DNIC‐induced neuronal inhibition in MIA animals, while pregabalin inhibited pre‐conditioned mechanically evoked neuronal responses but did not restore DNIC. Given in combination, tapentadol and pregabalin restored DNIC expression and also inhibited spinal neuronal responses. CONCLUSIONS: We propose that there is both central sensitization and an imbalance in inhibitory and facilitatory descending controls in MIA animals. The combination therapy of tapentadol and pregabalin restored descending noradrenergic inhibitory tone and also inhibited nociceptive transmission at the level of the spinal cord. SIGNIFICANCE: This study shows that pregabalin and tapentadol target different mechanisms of centrally driven chronic pain associated with osteoarthritis, and that when administered together can restore descending inhibitory tone whilst also tackling spinal neuronal hyperexcitability and may therefore provide superior analgesia.
format Online
Article
Text
id pubmed-6618140
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-66181402019-07-22 A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain Lockwood, Stevie Margaret Dickenson, Anthony H. Eur J Pain Original Articles BACKGROUND: Many Osteoarthritis (OA) patients report with clinical features to their pain that cannot be explained by purely peripheral mechanisms. Yet, the analgesic agents available that tackle centrally driven chronic pain often provide only partial pain relief, or have dose‐limiting side effects. We explored a combination therapy of the centrally acting analgesic agents tapentadol and pregabalin, to investigate if they could be used in combination to provide superior analgesia. METHODS: Using electrophysiological single‐unit recordings taken from spinal wide dynamic range neurons, Diffuse Noxious Inhibitory Controls (DNIC) were assessed as a marker of potential changes in descending controls in a monoiodoacetate (MIA) model of OA. We investigated if a subcutaneous injection of tapentadol or pregabalin, both alone and in combination, inhibited neuronal responses and restored the expression of DNIC, quantified as a reduction in neuronal firing in the presence of a conditioning noxious stimulus. RESULTS: Tapentadol restored DNIC‐induced neuronal inhibition in MIA animals, while pregabalin inhibited pre‐conditioned mechanically evoked neuronal responses but did not restore DNIC. Given in combination, tapentadol and pregabalin restored DNIC expression and also inhibited spinal neuronal responses. CONCLUSIONS: We propose that there is both central sensitization and an imbalance in inhibitory and facilitatory descending controls in MIA animals. The combination therapy of tapentadol and pregabalin restored descending noradrenergic inhibitory tone and also inhibited nociceptive transmission at the level of the spinal cord. SIGNIFICANCE: This study shows that pregabalin and tapentadol target different mechanisms of centrally driven chronic pain associated with osteoarthritis, and that when administered together can restore descending inhibitory tone whilst also tackling spinal neuronal hyperexcitability and may therefore provide superior analgesia. John Wiley and Sons Inc. 2019-03-22 2019-07 /pmc/articles/PMC6618140/ /pubmed/30821870 http://dx.doi.org/10.1002/ejp.1386 Text en © 2019 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation ‐ EFIC ® This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Lockwood, Stevie Margaret
Dickenson, Anthony H.
A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain
title A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain
title_full A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain
title_fullStr A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain
title_full_unstemmed A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain
title_short A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain
title_sort combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618140/
https://www.ncbi.nlm.nih.gov/pubmed/30821870
http://dx.doi.org/10.1002/ejp.1386
work_keys_str_mv AT lockwoodsteviemargaret acombinationpharmacotherapyoftapentadolandpregabalintotacklecentrallydrivenosteoarthritispain
AT dickensonanthonyh acombinationpharmacotherapyoftapentadolandpregabalintotacklecentrallydrivenosteoarthritispain
AT lockwoodsteviemargaret combinationpharmacotherapyoftapentadolandpregabalintotacklecentrallydrivenosteoarthritispain
AT dickensonanthonyh combinationpharmacotherapyoftapentadolandpregabalintotacklecentrallydrivenosteoarthritispain